Allergan Takes Aim At Lupin Over Lumigan ANDA

Law360, New York (November 14, 2011, 6:02 PM EST) -- Pharmaceutical giant Allergan Inc. on Friday sued a subsidiary of Indian drugmaker Lupin Ltd. in Texas federal court alleging infringement of a patent for glaucoma medication Lumigan in an ongoing bid to protect the drug from generic competition.

Allergan alleged that Lupin Pharmaceuticals Inc. infringed U.S. Patent Number 7,851,504, "Enhanced bimatoprost ophthalmic solution," when the drugmaker filed an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to produce and sell a generic version of Lumigan.

Lupin Pharmaceuticals claims in its ANDA...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.